{"id":3588,"date":"2020-10-01T12:43:01","date_gmt":"2020-10-01T10:43:01","guid":{"rendered":"https:\/\/www.ab-science.com\/?page_id=3588"},"modified":"2026-09-10T16:40:18","modified_gmt":"2026-09-10T14:40:18","slug":"investisseurs","status":"publish","type":"page","link":"https:\/\/ab-science.excalibra.com\/fr\/investisseurs\/","title":{"rendered":"Information actionnaires"},"content":{"rendered":"

[vc_row el_class=\u00a0\u00bbab2026-shell ab2026-section ab-investors-stock-heading\u00a0\u00bb][vc_column][vc_column_text]<\/p>\n

INFORMATION BOURSI\u00c8RE<\/p>\n

Cours de bourse.<\/span><\/h2>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=\u00a0\u00bbab2026-shell ab-investors-stock-grid\u00a0\u00bb][vc_column width=\u00a0\u00bb1\/3″][vc_raw_html]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[\/vc_raw_html][\/vc_column][vc_column width=\u00a0\u00bb2\/3″][vc_column_text]<\/p>\n

\n

Informations de cotation<\/p>\n

\n
\n
Cours de l\u2019action<\/dt>\n
Euronext<\/dd>\n<\/div>\n
\n
\u00c9ligibilit\u00e9<\/dt>\n
PEA Oui<\/strong><\/span>SRD Oui<\/strong><\/span><\/dd>\n<\/div>\n
\n
Code ISIN<\/dt>\n
FR0010557264<\/span><\/dd>\n<\/div>\n<\/dl>\n
<\/div>\n

Classification ICB<\/p>\n

\n
\n
4000<\/span> Industry<\/dt>\n
Health Care<\/dd>\n<\/div>\n
\n
4500<\/span> SupSector<\/dt>\n
Health Care<\/dd>\n<\/div>\n
\n
4570<\/span> Sector<\/dt>\n
Pharmaceuticals & Biotechnology<\/dd>\n<\/div>\n
\n
4577<\/span> SubSector<\/dt>\n
Pharmaceuticals<\/dd>\n<\/div>\n<\/dl>\n<\/div>\n

[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n

[vc_row el_class=\u00a0\u00bbab2026-section ab-investors-why-boxed ab2026-shell\u00a0\u00bb][vc_column][vc_column_text]<\/p>\n

\n

D\u00e9couvrez les atouts, les programmes et les perspectives d\u2019AB SCIENCE.<\/p>\n

Les atouts d\u2019AB Science.<\/span><\/h2>\n

Un positionnement diff\u00e9renciant fond\u00e9 sur le besoin m\u00e9dical, l\u2019innovation th\u00e9rapeutique et la ma\u00eetrise de la propri\u00e9t\u00e9 intellectuelle.<\/p>\n<\/div>\n

\n
\n
Important besoin m\u00e9dical et fort potentiel de march\u00e9<\/div>\n
\n
    \n
  • Les pathologies en d\u00e9veloppement pr\u00e9sentent toutes un fort besoin m\u00e9dical (maladie d\u2019Alzheimer, maladie de Charcot et leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb)<\/li>\n
  • Les programmes en d\u00e9veloppement combinent des pathologies \u00e0 fort potentiel de march\u00e9<\/strong> et des maladies orphelines<\/strong><\/li>\n<\/ul>\n<\/div>\n<\/div>\n
    \n
    M\u00e9canisme d\u2019action unique<\/div>\n
    \n
      \n
    • La mol\u00e9cule principale, le masitinib, est un inhibiteur de kinase ciblant s\u00e9lectivement le syst\u00e8me immunitaire via les mastocytes et les macrophages \/ la microglie<\/strong><\/li>\n
    • La nouvelle mol\u00e9cule, AB8939, est un d\u00e9stabilisateur synth\u00e9tique de microtubules de nouvelle g\u00e9n\u00e9ration capable de surmonter la multir\u00e9sistance \u00e0 l\u2019action des m\u00e9dicaments<\/li>\n<\/ul>\n<\/div>\n<\/div>\n
      \n
      Propri\u00e9t\u00e9 intellectuelle s\u00e9curis\u00e9e<\/div>\n
      \n
        \n
      • Propri\u00e9t\u00e9 intellectuelle d\u00e9tenue \u00e0 100\u00a0%<\/strong> par AB Science<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n

        [\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=\u00a0\u00bbab2026-shell ab2026-section ab-investors-docs-heading\u00a0\u00bb][vc_column][vc_column_text]<\/p>\n

        DOCUMENTATION FINANCI\u00c8RE<\/p>\n

        Documents pour les investisseurs.<\/span><\/h2>\n

        Retrouvez les derniers rapports financiers d\u2019AB SCIENCE.<\/p>\n

        [\/vc_column_text][\/vc_column][\/vc_row][vc_row content_placement=\u00a0\u00bbstretch\u00a0\u00bb equal_height=\u00a0\u00bbyes\u00a0\u00bb el_class=\u00a0\u00bbab2026-shell ab-investors-docs-grid\u00a0\u00bb][vc_column width=\u00a0\u00bb1\/2″ el_class=\u00a0\u00bbab-investor-doc-card\u00a0\u00bb][vc_column_text]<\/p>\n

        PDF<\/div>\n

        RAPPORT ANNUEL<\/p>\n

        Exercice 2025<\/h3>\n

        Rapport annuel du groupe AB Science au 31 d\u00e9cembre 2025.<\/p>\n

        [\/vc_column_text]